Springer Nature is making SARS-CoV-2 and COVID-19 research free View research | View latest news | Sign up for updates

NICE requires further evidence on erenumab

    • 1 Accesses

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      National Health Service

    2. 2.

      see PharmacoEconomics & Outcomes News 838 p36; 803425772

    Reference

    1. NICE. Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine. Internet Document : 4 Feb 2020. Available from: URL: https://www.nice.org.uk/news/article/appeal-panel-rules-that-nice-needs-to-request-evidence-for-erenumab-effectiveness-in-subgroup-of-people-with-chronic-migraine

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    NICE requires further evidence on erenumab. PharmacoEcon Outcomes News 846, 37 (2020). https://doi.org/10.1007/s40274-020-6576-0

    Download citation